Active ingredientCarenoprazan HClCat. No. P-C050-001CAS 2209911-80-6Family · Pharmaceutical analytical standards
Carenoprazan
A new-generation potassium-competitive acid blocker (P-CAB) developed in China, which reduces stomach acid secretion: in the 2020s it reached phase III trials for duodenal ulcer and is also being studied for reflux oesophagitis. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Like the other P-CABs it binds the stomach's proton pump reversibly, competing with potassium: unlike classic proton pump inhibitors it also blocks pumps that are not yet active.
Go to the active ingredient →Active ingredientCarenoprazan HClCat. No. P-C050-001CAS 2209911-80-6
Isotopically labelledCarenoprazan M9-d3 HClCat. No. P-C050-003
Isotopically labelledCarenoprazan-d3Cat. No. P-C050-005
NitrosamineN-Nitroso CarenoprazanCat. No. P-C050-006
ImpurityCarenoprazan M9Cat. No. P-C050-007CAS 2231094-87-2No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.